TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12151444

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Physician-Administered Sedation (PAS)
Number of subjects: 106
Study: 10554120

Group type: EXPERIMENTAL
Intervention: HBcAg stimulation in group 1 (raised alanine transferase levels)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HBcAg stimulation in group 1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HBcAg stimulation in all groups
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HBcAg stimulation in groups 1 and 2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LPS stimulation in group 1
Number of subjects: 54

Group type: COMPARATOR
Intervention: HBV antigens or LPS stimulation in children of carrier mothers
Number of subjects: 54
Study: 8622041

Group type: EXPERIMENTAL
Intervention: Protocol 77-04 (15 cycles of CTX, ADR, PRED, VCR, high-dose MTX, and IT therapy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Protocol 89-C-41 (high-risk patients received CODOX-M and IVAC; low-risk patients received CODOX-M)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) in high-risk patients
Number of subjects: 72
Study: 8365461

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 50
Study: 3780987

Group type: EXPERIMENTAL
Intervention: (modified) radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast conserving treatment (tumorectomy followed by radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups (mastectomy and breast conserving treatment)
Number of subjects: 0
Study: 29655257

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 27466252

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Laryngoscopy with oxygen cannula (DLO2)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Truview PCD videolaryngoscope (VLO2)
Number of subjects: 457
Study: 25088437

Group type: EXPERIMENTAL
Intervention: Intensive therapy (target HbA1c less than 42 mmol/mol or less than 6·0%)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy (target HbA1c 53‐63 mmol/mol or 7·0‐7·9%)
Number of subjects: 10251
Study: 22343976

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80-85% 1RM (85%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60-65% 1RM (65%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both exercise intensities
Number of subjects: 12
Study: 20186278

Group type: EXPERIMENTAL
Intervention: IL-2 for 5 consecutive days every 8 weeks for 3 cycles
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: IL-2 plus ART for 5 consecutive days every 8 weeks for 3 cycles with 10 days of ART around each IL-2 cycle
Number of subjects: 267

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 267
Study: 18499354

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 361
Study: 15980686

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/ritonavir (RTV)‐containing highly active antiretroviral (ARV) therapy regimens
Number of subjects: 0
Study: 12705178

Group type: EXPERIMENTAL
Intervention: Triclabendazole (10 mg/kg body weight, two consecutive oral doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triclabendazole (10 mg/kg body weight) + Vitamin C (1000 mg/day) + Vitamin E (600 mg/day) for two months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (10 healthy subjects)
Number of subjects: 32
Study: 10589540

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study: 8756736

Group type: EXPERIMENTAL
Intervention: Alpha 1-antitrypsin activity in blood after operation in patients with prostatic carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha 1-antitrypsin activity in blood after operation in patients with benign prostatic hyperplasia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostatic carcinoma
Number of subjects: 0
Study: 2017331

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 40
Study: 6784224

Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg twice a day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Penicillin V 250 mg four times a day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 mg every 8 hr
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study: 30698316

Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG (MED/CABG)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Severe CCI score
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Interaction between CCI score and treatment effect
Number of subjects: 1212
Study: 28854580

Group type: EXPERIMENTAL
Intervention: 150 IU recombinant FSH (rFSH)
Number of subjects: 124
Study: 26346470

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD), containing 12.5 μg/250 ml, taken twice a day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain doogh (PD), containing no vitamin D, taken twice a day for 12 weeks
Number of subjects: 60
Study: 23287836

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - 12 weeks of supervised squat exercise, 3 times a week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG) - encouraged to follow current exercise guidelines
Number of subjects: 21
Study: 22724916

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study: 19585769

Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED) in training combat support hospital (CSH) setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED) in combat forward operating base (FOB) setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard manual defibrillation in training combat support hospital (CSH) setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard manual defibrillation in combat forward operating base (FOB) setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED)
Number of subjects: 0
Study: 17965789

Group type: EXPERIMENTAL
Intervention: Bowel preparation (lactulose 2 days before surgery and rectal enema on the day of surgery)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No bowel preparation (Control Group II)
Number of subjects: 127
Study: 15379121

Group type: EXPERIMENTAL
Intervention: Maintenance therapy consisting of 5-day courses of cytostatic drugs alternating or not alternating with 5-day courses of ATRA
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patients with hyperleukocytosis
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 68
Study: 11803986

Group type: EXPERIMENTAL
Intervention: CrossAction toothbrush
Number of subjects: 91

Group type: COMPARATOR
Intervention: X‐Aktiv toothbrush
Number of subjects: 91
Study: 10990440

Group type: EXPERIMENTAL
Intervention: GH secretagogues
Number of subjects: 0

Group type: COMPARATOR
Intervention: GH79
Number of subjects: 0
Study: 3164341

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30620688

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the eustachian tube (BDET) + medical management (MM)
Number of subjects: 143
Study: 27041109

Group type: EXPERIMENTAL
Intervention: Wave‐One instrumentation (G3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ProTaper Universal instrumentation (G2)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Hand instrumentation (G1)
Number of subjects: 96
Study: 26287319

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PCF) with surgery
Number of subjects: 346

Group type: COMPARATOR
Intervention: Preoperative chemotherapy alone
Number of subjects: 346
Study: 22992376

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 70
Study: 21076271

Group type: EXPERIMENTAL
Intervention: HBV-active antiretroviral therapy (ART) for 48 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: HIV-HBV co-infected patients
Number of subjects: 16
Study: 18640000

Group type: EXPERIMENTAL
Intervention: Web-based tailored-feedback intervention promoting the Mediterranean diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Minimal dietary feedback and general healthy-eating brochures (Control)
Number of subjects: 53
Study: 17056969

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12712958

Group type: EXPERIMENTAL
Intervention: AIDSVAX vaccine
Number of subjects: 0
Study: 10736331

Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) - 10 g/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: Triacylglycerol (TG) - 10 g/d (control)
Number of subjects: 38
Study: 8737101

Group type: EXPERIMENTAL
Intervention: 1 g MgSO4 bolus followed by 4 g MgSO4 for 24 h
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1 g MgSO4 bolus followed by 14 g MgSO4 for 24 h
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 29
Study: 1560192

Group type: EXPERIMENTAL
Intervention: Hormone replacement treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Basal conditions (before oophorectomy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One month after oophorectomy
Number of subjects: 30
Study: 2862464

Group type: EXPERIMENTAL
Intervention: Dry powdered surfactant (25 mg) insufflated through the endotracheal tube
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 30879731

Group type: EXPERIMENTAL
Intervention: High prenatal social support
Number of subjects: 262
Study: 29603805

Group type: EXPERIMENTAL
Intervention: Progressive resistance band training
Number of subjects: 99

Group type: COMPARATOR
Intervention: General physical exercise
Number of subjects: 99
Study: 27055221

Group type: EXPERIMENTAL
Intervention: DSAEK surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (cataract patients)
Number of subjects: 32
Study: 24981461

Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23163142

Group type: EXPERIMENTAL
Intervention: Qudu Granule (QG), orally taken, 5 g each time, 3 times a day for over 12 months.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Niaoduqing granule (NG), orally taken, 5 g each time, 3 times a day for over 12 months.
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Qudu Granule (QG)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Niaoduqing granule (NG)
Number of subjects: 166
Study: 20380284

Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy with Temodal (75 mg/m2)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Radiation therapy only (60 Gy, fractionated into 5 x 2 Gy weekly)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups (Chemo-radiotherapy and RT)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy with Temodal
Number of subjects: 179
Study: 18083668

Group type: EXPERIMENTAL
Intervention: Care from respiratory nurse
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care from respiratory physician
Number of subjects: 187
Study: 15653517

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus strain L-92 (100 mL of heat-treated fermented milk)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (acidified milk without lactic acid bacteria)
Number of subjects: 49
Study: 12567031

Group type: EXPERIMENTAL
Intervention: Standardized facilitation of motor-evoked potentials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Deltoid motor-evoked potentials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Changes in motor-evoked potential amplitude
Number of subjects: 20
Study: 10235522

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia containing 2 mM adenosine and adenosine infusion (200 microg/kg/min) before and after aortic crossclamp removal
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia containing 2 mM adenosine
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 253
Study: 8909453

Group type: EXPERIMENTAL
Intervention: recombinant human ciliary neurotrophic factor (rhCNTF) at doses ranging from 2 to 100 micrograms/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: daily subcutaneous rhCNTF at doses < or = 5 micrograms/kg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: daily subcutaneous rhCNTF at higher doses
Number of subjects: 72
Study: 1810522

Group type: EXPERIMENTAL
Intervention: Topical 5% meclofenamic acid gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral sodium meclofenamate capsules
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium naproxen capsules
Number of subjects: 90
Study: 6406441

Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bupropion 450 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30521423

Group type: EXPERIMENTAL
Intervention: Normoxic hypercapnia (NH)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hyperoxic hypercapnia (HH)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 31
Study: 30081458

Group type: EXPERIMENTAL
Intervention: Annoyance due to aircraft noise
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Noise sensitivity
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Exposure to aircraft noise in dB
Number of subjects: 1244
Study: 27021017

Group type: EXPERIMENTAL
Intervention: Power nap: 10-20 min sleep
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Long nap: 50-80 min sleep
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wake condition: 45-min wake
Number of subjects: 35
Study: 24858886

Group type: EXPERIMENTAL
Intervention: Parental tobacco prevention intervention
Number of subjects: 520
Study: 22869581

Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 2 mg/kg/day for 7 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 4 mg/kg/day for 7 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 6 mg/kg/day for 7 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy
Number of subjects: 143
Study: 20962434

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SC‐70303
Number of subjects: 0
Study: 17055329

Group type: EXPERIMENTAL
Intervention: APO (apomorphine) at typically effective dose (TED)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: APO+2 (apomorphine at TED+0.2mL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PL) at volume equal to TED
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo+2 (PL+2 at volume equal to TED+0.2mL)
Number of subjects: 62
Study: 14530901

Group type: COMPARATOR
Intervention: Memantine (0 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Memantine (15 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Memantine (30 mg)
Number of subjects: 18
Study: 11815315

Group type: EXPERIMENTAL
Intervention: Whole-kernel rye bread
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-meal rye bread containing oat beta-glucan concentrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dark durum wheat pasta
Number of subjects: 20

Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 20
Study: 9710711

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 35 mg ethinylestradiol and 2 mg cyproterone acetate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 30 mg ethinylestradiol and 150 mg desogestrel
Number of subjects: 67
Study: 7663660

Group type: EXPERIMENTAL
Intervention: Aerosolised rhDNase 2.5 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aerosolised rhDNase 2.5 mg twice daily (open-label phase)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (open-label phase)
Number of subjects: 70
Study: 2667508

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 271
Study: 65660

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 4031

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4031
Study: 31445481

Group type: EXPERIMENTAL
Intervention: Routine auditory‐verbal approach plus new cognitive-based intervention protocol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine auditory‐verbal approach
Number of subjects: 51
Study: 27869649

Group type: EXPERIMENTAL
Intervention: Calcipotriol (0.005% ointment) combined with 5-fluorouracil (5% cream)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Vaseline plus 5-fluorouracil (5% cream)
Number of subjects: 131
Study: 26384238

Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide
Number of subjects: 235

Group type: COMPARATOR
Intervention: ATRA and idarubicin
Number of subjects: 235
Study: 23644718

Group type: EXPERIMENTAL
Intervention: Invasive Coolgard(®) cooling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non‐invasive ArcticSun(®) surface cooling
Number of subjects: 80
Study: 21593096

Group type: EXPERIMENTAL
Intervention: Full length 5 degree lateral wedged insoles worn daily for 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Flat control insoles worn daily for 12 months
Number of subjects: 200
Study: 19389040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16621098

Group type: EXPERIMENTAL
Intervention: Inter-subtype recombinant genome
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant LTRs
Number of subjects: 61
Study: 15245943

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SpA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 72
Study: 11726007

Group type: EXPERIMENTAL
Intervention: Humalog Mix25 (Mix25)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Glyburide (GB)
Number of subjects: 172
Study: 9215091

Group type: EXPERIMENTAL
Intervention: Valaciclovir (500 mg once daily)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 8314294

Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime i.v. as a single bolus 20 minutes before surgical incision
Number of subjects: 66

Group type: COMPARATOR
Intervention: 1.5 g cefuroxime i.v. injected 20 minutes after incision
Number of subjects: 66
Study: 3685069

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31623493

Group type: COMPARATOR
Intervention: Pregabalin controlled-release (CR) 165 and 330 mg/day
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 28228410

Group type: EXPERIMENTAL
Intervention: 3-piece IOL model
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1-piece IOL model
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative parameters (axial length, anterior chamber depth)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regression analysis
Number of subjects: 50
Study: 26626148

Group type: COMPARATOR
Intervention: Low-dose GTP (500 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: High-dose GTP (1,000 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: GTP treatment (both doses)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 23300343

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) 40 mg within 6 hours after TURBT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Urinary alkalinization prior to MMC
Number of subjects: 49

Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Standard group vs Optimized group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group vs Optimized group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group vs Standard group
Number of subjects: 49
Study: 21563963

Group type: EXPERIMENTAL
Intervention: Phytothermotherapy for 10 days
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (regular outpatient care)
Number of subjects: 218
Study: 18654069

Group type: EXPERIMENTAL
Intervention: guaifenesin/pseudoephedrine
Number of subjects: 601

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 601
Study: 16239607

Group type: EXPERIMENTAL
Intervention: Heavy cycle ergometer exercise under hypoxic conditions (3,810 m)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxic exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heavy cycle ergometer exercise at altitude (3,810 m)
Number of subjects: 8
Study: 14769323

Group type: EXPERIMENTAL
Intervention: Primary closure with two interrupted sutures using 3‐0 chromic catgut (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Secondary healing (Group 2)
Number of subjects: 39
Study: 11580731

Group type: EXPERIMENTAL
Intervention: Vaginal palpation test
Number of subjects: 20
Study: 9212308

Group type: EXPERIMENTAL
Intervention: Human insulin (H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Porcine insulin (P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both insulins
Number of subjects: 20